Silver Book Fact

Potential cost effectiveness of shingles vaccines

The projected cost-effectiveness of a shingles vaccine for adults age 60 and older was estimated at $15,390 – $22,474 from the payer perspective, and $14,450 to $21,524 from the societal perspective.

Pellesier J, Brisson M, Levin M. Evaluation of the Cost-Effectiveness in the United States of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. Vaccine. 2007; 25(49): 8326-37. http://www.ncbi.nlm.nih.gov/pubmed/17980938

Reference

Title
Evaluation of the Cost-Effectiveness in the United States of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
Publication
Vaccine
Publication Date
2007
Authors
Pellesier J, Brisson M, Levin M
Volume & Issue
Volume 25, Issue 49
Pages
8326-37
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value
  • Future Value

Related Facts

  • Staff vaccination in nursing homes reduces mortality rates of residents
    Mortality rates in nursing home residents were 42% lower in facilities with higher staff vaccination coverage compared with control facilities.  
  • Vaccines save lives and money
    Between 2001 and 2010, vaccine use prevented an estimated 170,000 severe pneumococcal infections and 10,000 deaths, and saved an estimated $310 million in direct medical costs each year.  
  • Cost of pneumonia vaccine
    Addition of PCV13 (13-valent pneumococcal conjugate vaccine) to previously recommended pneumococcal polysaccharide vaccine for immunocompromised adults cost $70,937 per quality adjusted life year compared to no vaccine.  
  • Over 8 years infection control practices saved ~27,000 lives and $1.8 billion
    Infection control practices saved an estimated 27,000 lives and $1.8 billion in medical costs between 2001 and 2009.  
  • Shingles vaccine reduces incidence by >50%
    Use of a live attenuated VZV (varicella-zoster vaccine) in a randomized trial reduced the incidence of shingles by 51.3%.